GAEA POPE-DAUM: Open Payments
NPI 1679878193 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$462 in 18 payments from 9 companies in 2025. Trend: 2023 $332 · 2024 $1,837 · 2025 $462
Food & beverage: $462
| Company | Payments | Amount |
|---|---|---|
| Tris Pharma Inc | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Neurocrine BioSciences, Inc. | 2 | $59 |
| Axsome Therapeutics, Inc. | 2 | $55 |
| Janssen Pharmaceuticals, Inc | 1 | $39 |
| Sage Therapeutics, LLC | 1 | $28 |
| MERZ NORTH AMERICA, INC. | 1 | $26 |
| ABBVIE INC. | 1 | $23 |
| bioMerieux Inc | 1 | $20 |
Products named: Dyanavel XR, TRINTELLIX, INGREZZA, Auvelity, INVEGA SUSTENNA, ZURZUVAE, Xeomin, VRAYLAR.
Industry payments across CA — which companies pay providers there.
